MAPK inhibitor sensitivity scores predict sensitivity driven by the immune infiltration in pediatric low-grade gliomas

[1]  David C. Jones,et al.  Molecular diagnostics enables detection of actionable targets: the Pediatric Targeted Therapy 2.0 registry. , 2022, European journal of cancer.

[2]  David C. Jones,et al.  CTNI-30. LOGGIC/FIREFLY-2: A PHASE 3, RANDOMIZED TRIAL OF TOVORAFENIB VS. CHEMOTHERAPY IN PEDIATRIC PATIENTS WITH NEWLY DIAGNOSED LOW-GRADE GLIOMA HARBORING AN ACTIVATING RAF ALTERATION , 2022, Neuro-Oncology.

[3]  Allison P. Heath,et al.  OpenPBTA: The Open Pediatric Brain Tumor Atlas , 2023, Cell genomics.

[4]  J. Barnholtz-Sloan,et al.  CBTRUS Statistical Report: Pediatric Brain Tumor Foundation Childhood and Adolescent Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2014-2018. , 2022, Neuro-oncology.

[5]  David C. Jones,et al.  BH3 mimetics targeting BCL-XL impact the senescent compartment of pilocytic astrocytoma. , 2022, Neuro-oncology.

[6]  David C. Jones,et al.  The first-in-class ERK inhibitor ulixertinib shows promising activity in MAPK-driven pediatric low-grade glioma models. , 2022, Neuro-oncology.

[7]  David C. Jones,et al.  LGG-14. LOGGIC (Low Grade Glioma in Children) Core BioClinical Data Bank: Establishment and added clinical value of an international molecular diagnostic registry for pediatric low-grade glioma patients , 2022, Neuro-Oncology.

[8]  E. Li,et al.  Blocking STAT3 signaling augments MEK/ERK inhibitor efficacy in esophageal squamous cell carcinoma , 2022, Cell Death & Disease.

[9]  V. W. Lui,et al.  Precision drugging of the MAPK pathway in head and neck cancer , 2022, NPJ genomic medicine.

[10]  A. Letai,et al.  Combination therapy targeting Erk1/2 and CDK4/6i in relapsed refractory multiple myeloma , 2022, Leukemia.

[11]  Yaoting Gui,et al.  Mutations of MSH5 in nonobstructive azoospermia (NOA) and rescued via in vivo gene editing , 2022, Signal Transduction and Targeted Therapy.

[12]  Matthew D. Dun,et al.  Pharmaco-proteogenomic profiling of pediatric diffuse midline glioma to inform future treatment strategies , 2021, Oncogene.

[13]  Y. Carmi,et al.  MEK1/2 inhibition transiently alters the tumor immune microenvironment to enhance immunotherapy efficacy against head and neck cancer , 2021, Journal for ImmunoTherapy of Cancer.

[14]  S. Stasheff,et al.  Treatment during a developmental window prevents NF1-associated optic pathway gliomas by targeting Erk-dependent migrating glial progenitors. , 2021, Developmental cell.

[15]  G. Reifenberger,et al.  The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. , 2021, Neuro-oncology.

[16]  J. Barnholtz-Sloan,et al.  Reimagining Pilocytic Astrocytomas in the Context of Pediatric Low-Grade Gliomas. , 2021, Neuro-oncology.

[17]  P. Howarth,et al.  Mapping atopic dermatitis and anti-IL-22 response signatures to Type 2-low severe neutrophilic asthma. , 2021, The Journal of allergy and clinical immunology.

[18]  J. Vencovský,et al.  Plasma Hsp90 levels in patients with systemic sclerosis and relation to lung and skin involvement: a cross-sectional and longitudinal study , 2021, Scientific Reports.

[19]  Qiming Wang,et al.  MEK inhibitors for the treatment of non-small cell lung cancer , 2021, Journal of Hematology & Oncology.

[20]  A. Regev,et al.  Single cell RNA sequencing of human microglia uncovers a subset associated with Alzheimer’s disease , 2020, Nature Communications.

[21]  Guo Ci Teo,et al.  Integrated Proteogenomic Characterization across Major Histological Types of Pediatric Brain Cancer , 2020, Cell.

[22]  David T. W. Jones,et al.  Response to trametinib treatment in progressive pediatric low-grade glioma patients , 2020, Journal of Neuro-Oncology.

[23]  R. Stephens,et al.  ssGSEA score-based Ras dependency indexes derived from gene expression data reveal potential Ras addiction mechanisms with possible clinical implications , 2020, Scientific Reports.

[24]  Marilyn M. Li,et al.  Integrated Molecular and Clinical Analysis of 1,000 Pediatric Low-Grade Gliomas. , 2020, Cancer cell.

[25]  D. Martin,et al.  Integrated molecular characterisation of the MAPK pathways in human cancers reveals pharmacologically vulnerable mutations and gene dependencies , 2020, Communications Biology.

[26]  T. Bale.  FGFR- gene family alterations in low-grade neuroepithelial tumors , 2020, Acta Neuropathologica Communications.

[27]  Min Wu,et al.  Applications of genome editing technology in the targeted therapy of human diseases: mechanisms, advances and prospects , 2020, Signal Transduction and Targeted Therapy.

[28]  J. D. Mills,et al.  The coding and non-coding transcriptional landscape of subependymal giant cell astrocytomas , 2019, Brain : a journal of neurology.

[29]  M. Cabanillas,et al.  Targeted Therapy for Advanced Thyroid Cancer: Kinase Inhibitors and Beyond. , 2019, Endocrine reviews.

[30]  M. Sciandrone,et al.  Modeling cancer drug response through drug-specific informative genes , 2019, Scientific Reports.

[31]  O. Witt,et al.  Natural History of Pediatric Low-Grade Glioma Disease - First Multi-State Model Analysis , 2019, Journal of Cancer.

[32]  T. Kuner,et al.  Glutamatergic synaptic input to glioma cells drives brain tumour progression , 2019, Nature.

[33]  Mariella G. Filbin,et al.  Mitogenic and progenitor gene programmes in single pilocytic astrocytoma cells , 2019, Nature Communications.

[34]  Shawn M. Gillespie,et al.  Electrical and synaptic integration of glioma into neural circuits , 2019, Nature.

[35]  D. Dillon,et al.  Results from a single arm, single stage phase II trial of trametinib and GSK2141795 in persistent or recurrent cervical cancer. , 2019, Gynecologic oncology.

[36]  David J. Klinke,et al.  An elastic-net logistic regression approach to generate classifiers and gene signatures for types of immune cells and T helper cell subsets , 2019, BMC Bioinformatics.

[37]  Andrew E Teschendorff,et al.  Avoiding common pitfalls in machine learning omic data science , 2018, Nature Materials.

[38]  J. Bajramovic,et al.  An Overview of in vitro Methods to Study Microglia , 2018, Front. Cell. Neurosci..

[39]  M. Sawyer,et al.  Phase 1b investigation of the MEK inhibitor binimetinib in patients with advanced or metastatic biliary tract cancer , 2018, Investigational New Drugs.

[40]  Liguo Zhang,et al.  Unifying cancer and normal RNA sequencing data from different sources , 2018, Scientific Data.

[41]  Steven J. M. Jones,et al.  Oncogenic Signaling Pathways in The Cancer Genome Atlas. , 2018, Cell.

[42]  M. Boerries,et al.  BRAF inhibition upregulates a variety of receptor tyrosine kinases and their downstream effector Gab2 in colorectal cancer cell lines , 2018, Oncogene.

[43]  Hongyang Wang,et al.  Vitamin C preferentially kills cancer stem cells in hepatocellular carcinoma via SVCT-2 , 2018, npj Precision Oncology.

[44]  A. Godwin,et al.  Developing a genetic signature to predict drug response in ovarian cancer , 2017, Oncotarget.

[45]  Roland Eils,et al.  OTP: An automatized system for managing and processing NGS data. , 2017, Journal of biotechnology.

[46]  Steven D Chang,et al.  Single-Cell RNAseq analysis of infiltrating neoplastic cells at the migrating front of human glioblastoma , 2017, bioRxiv.

[47]  P. Poulikakos,et al.  New perspectives for targeting RAF kinase in human cancer , 2017, Nature Reviews Cancer.

[48]  K. Skullerud,et al.  A European randomised controlled trial of the addition of etoposide to standard vincristine and carboplatin induction as part of an 18-month treatment programme for childhood ( 16 years ) low grade glioma e A final report , 2017 .

[49]  Edward F. Chang,et al.  Tumor Evolution of Glioma-Intrinsic Gene Expression Subtypes Associates with Immunological Changes in the Microenvironment. , 2017, Cancer cell.

[50]  G. Nan,et al.  The extracellular signal-regulated kinase 1/2 pathway in neurological diseases: A potential therapeutic target (Review) , 2017, International journal of molecular medicine.

[51]  K. Kelly,et al.  A Phase 1/1b Study Evaluating Trametinib Plus Docetaxel or Pemetrexed in Patients With Advanced Non–Small Cell Lung Cancer , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[52]  Jiwei Huang,et al.  The selective MEK1 inhibitor Selumetinib enhances the antitumor activity of everolimus against renal cell carcinoma in vitro and in vivo , 2017, Oncotarget.

[53]  M. Teufel,et al.  Phase I/II Study of Refametinib (BAY 86-9766) in Combination with Gemcitabine in Advanced Pancreatic cancer , 2017, Targeted Oncology.

[54]  David T. W. Jones,et al.  Establishment and application of a novel patient-derived KIAA1549:BRAF-driven pediatric pilocytic astrocytoma model for preclinical drug testing , 2016, Oncotarget.

[55]  G. Giaccone,et al.  Selumetinib with and without erlotinib in KRAS mutant and KRAS wild-type advanced nonsmall-cell lung cancer. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[56]  Dung-Tsa Chen,et al.  A Phase I Trial of Trametinib in Combination with Sorafenib in Patients with Advanced Hepatocellular Cancer. , 2020, The oncologist.

[57]  Helmut Kettenmann,et al.  The role of microglia and macrophages in glioma maintenance and progression , 2015, Nature Neuroscience.

[58]  Joshua M. Korn,et al.  High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response , 2015, Nature Medicine.

[59]  S. Cook,et al.  MEK1 and MEK2 inhibitors and cancer therapy: the long and winding road , 2015, Nature Reviews Cancer.

[60]  Antoni Ribas,et al.  Non-genomic and Immune Evolution of Melanoma Acquiring MAPKi Resistance , 2015, Cell.

[61]  Alfredo Quinones-Hinojosa,et al.  The FGFR/MEK/ERK/brachyury pathway is critical for chordoma cell growth and survival. , 2014, Carcinogenesis.

[62]  Christof Fellmann,et al.  Disruption of CRAF-mediated MEK activation is required for effective MEK inhibition in KRAS mutant tumors. , 2014, Cancer cell.

[63]  G. Getz,et al.  Inferring tumour purity and stromal and immune cell admixture from expression data , 2013, Nature Communications.

[64]  A. Resnick,et al.  Paradoxical activation and RAF inhibitor resistance of BRAF protein kinase fusions characterizing pediatric astrocytomas , 2013, Proceedings of the National Academy of Sciences.

[65]  Sridhar Ramaswamy,et al.  Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells , 2012, Nucleic Acids Res..

[66]  M. Cascante,et al.  Relevance of the MEK/ERK Signaling Pathway in the Metabolism of Activated Macrophages: A Metabolomic Approach , 2012, The Journal of Immunology.

[67]  J. D. de Groot,et al.  Glutamate and the biology of gliomas , 2011, Glia.

[68]  T. Merchant,et al.  Survival and long-term health and cognitive outcomes after low-grade glioma. , 2011, Neuro-oncology.

[69]  B. Taylor,et al.  The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner , 2010, Proceedings of the National Academy of Sciences.

[70]  C. Sander,et al.  V600EBRAF is associated with disabled feedback inhibition of RAF–MEK signaling and elevated transcriptional output of the pathway , 2009, Proceedings of the National Academy of Sciences.

[71]  U. Rapp,et al.  Phospho-ERK staining is a poor indicator of the mutational status of BRAF and NRAS in human melanoma. , 2008, The Journal of investigative dermatology.

[72]  Jae K. Lee,et al.  A strategy for predicting the chemosensitivity of human cancers and its application to drug discovery , 2007, Proceedings of the National Academy of Sciences.

[73]  A. Dupuy,et al.  Critical review of published microarray studies for cancer outcome and guidelines on statistical analysis and reporting. , 2007, Journal of the National Cancer Institute.

[74]  J. Mesirov,et al.  GenePattern 2.0 , 2006, Nature Genetics.

[75]  Jeffrey T. Chang,et al.  Oncogenic pathway signatures in human cancers as a guide to targeted therapies , 2006, Nature.